688068 Beijing Hotgen Biotech Co.,Ltd
- 29.85
- +0.32+1.08%
Beijing Hotgen Biotech Co.,Ltd News
Hot Scene Biotech (688068.SH): Net profit of RMB 5,0554,800 for the first quarter decreased by 91.42% year-on-year
On April 29, Ge Longhui (688068.SH) released its report for the first quarter of 2024, achieving operating income of 116 million yuan, a year-on-year decrease of 42.78%; net profit attributable to shareholders of listed companies of 50554,800 yuan, a year-on-year decrease of 91.42%; and net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 339.464 million yuan, with basic earnings per share of 0.06 yuan.
Hejing Biotech (688068.SH): A total cost of 92.06 million yuan to buy back 3.14% of the shares
Gelonghui, April 16, 丨 Hot View Biotech (688068.SH) announced that by the close of trading on April 15, 2024, the company had repurchased 2,893,010 shares through centralized bidding transactions, accounting for 3.14% of the company's total share capital. The highest price of the repurchase transaction was 33.79 yuan/share, the lowest price was 27.28 yuan/share, and the total amount of capital paid was RMB 92,016,460.62 (excluding transaction fees such as stamp duty and transaction commissions).
Hot View Biotech (688068.SH): Proposes to acquire 100% of Kaijing Gene's shares held by an affiliated company
On April 15, Gelonghui Biotech (688068.SH) announced that in order to integrate the in-vitro diagnosis business of the company and its affiliated companies, the company plans to acquire 100% of the shares of Beijing Kaijing Gene Technology Co., Ltd. (“Kaijing Gene”) held by the affiliated company Beijing Shunjing Biomedical Technology Co., Ltd. (“Shunjing Pharmaceutical”). The transfer price for this transaction was 11 million yuan, all of which were paid in cash.
Hejing Biotech (688068.SH) plans to acquire 100% of Kaijing Gene's shares to integrate the in vitro diagnostic business
According to Zhitong Finance App News, Hot View Biotech (688068.SH) announced that in order to integrate the in vitro diagnosis business of the company and related companies, the company plans to acquire 100% of the shares of Beijing Kaijing Gene Technology Co., Ltd. (“Shunjing Gene”) held by the affiliated company Beijing Shunjing Biomedical Technology Co., Ltd. (“Shunjing Pharmaceutical”). The transfer price for this transaction was 11 million yuan, all of which were paid in cash. According to reports, Kaijing Gene was founded in 2016 and is a biotechnology service company specializing in R&D, production and sales of in vitro diagnostic reagent raw materials. It is proposed for in vitro diagnostic reagent manufacturers
Hot View Biotech (688068.SH): Foreign trade is currently progressing well
Gelonghui, April 11, 丨 Hot View Biotech (688068.SH) Investor Relations Activity Record Sheet shows that the company has always insisted on placing equal emphasis on domestic and foreign markets and is actively expanding overseas markets. Currently, foreign trade is progressing well. The company has established two professional marketing management teams, international and domestic, and has set up subsidiaries in India, Hong Kong and the United States, and set up offices in Thailand to develop global business.
Hot View Biotech (688068.SH): A total cost of 87.02 million yuan to buy back 2.95% of the shares
Gelonghui, April 2, 丨 Hot View Biotech (688068.SH) announced that by the close of trading on March 29, 2024, the company had repurchased 2,718,010 shares through centralized bidding transactions, accounting for 2.95% of the company's total share capital, an increase of 0% compared with the previous disclosure. The highest price of the repurchase transaction was 33.79 yuan/share, the lowest price was 27.28 yuan/share, and the total amount of capital paid was RMB 87,021,704.94 (excluding transaction fees such as stamp duty and transaction fees).
Hot View Biotech (688068.SH): 2.95% of shares have been repurchased
Gelonghui, March 4, 丨 Hot View Biotech (688068.SH) announced that by the close of trading on February 29, 2024, the company had repurchased 2,718,000 shares through centralized bidding transactions, accounting for 2.95% of the company's total share capital, an increase of 0.27% compared with the previous disclosure. The highest price of the repurchase transaction was 33.79 yuan/share, the lowest price was 27.28 yuan/share, and the total amount of capital paid was RMB 87.0217 million (excluding transaction fees such as stamp duty and transaction fees).
Hot View Biotech (688068.SH) performance report: 2023 net profit of 30.1612 million yuan fell 96.81% year on year
Gelonghui, Feb. 28, 丨 Greenview Biotech (688068.SH) announced its 2023 annual performance report. During the reporting period, the company achieved operating income of 541.1467 million yuan, a decrease of 84.78% compared with the same period last year; realized net profit attributable to owners of the parent company of 30.1612 million yuan, a decrease of 96.81% compared with the same period last year; realized net profit attributable to the owners of the parent company after deducting non-recurring gains and losses - 56.4366 million yuan, a decrease of 105.99% compared with the same period last year.
Hejing Biotech (688068.SH) has repurchased 2.68% of its shares at a cost of 79.11 million yuan
Hotview Biotech (688068.SH) announced that as of the close of trading on February 19, 2024, the company passed centralized bidding...
Hot View Biotech (688068.SH): Initial repurchase of 971,600 shares
Gelonghui, Feb. 19, 丨 Hot View Biotech (688068.SH) announced that on February 8, 2024, the company repurchased 971,600 shares for the first time through centralized bidding transactions, accounting for 1.05% of the company's total share capital. The highest purchase price was RMB 31.64 yuan/share, the lowest price was RMB 27.28 per share, and the total amount paid was RMB 29.708 million (excluding transaction fees such as stamp duty and transaction commissions).
Hot View Biotech (688068.SH): Plans to transfer 10% of Yaojing Gene's shares for 10 million yuan
Gelonghui, Feb. 5, 丨 Hot View Biotech (688068.SH) announced that the company and Mr. Lin Changqing signed an “Equity Transfer Agreement” in Beijing on February 2, 2024. The company plans to transfer 10% of its Yaojing Gene shares to Mr. Lin Changqing at a consideration of RMB 10 million. Mr. Lin Changqing is the actual controller, chairman and general manager of the company, and is a natural person related to the company; this transaction constitutes a related transaction and does not constitute a major asset restructuring.
Hejing Biotech (688068.SH) and its subsidiaries have recently obtained 13 medical device registration certificates and 60 overseas qualification certifications
Hejing Biotech (688068.SH) issued an announcement. The company and its subsidiaries will be held from November 2023 to 2024...
Hejing Biotech (688068.SH) issued a pre-cut. Net profit is expected to be 24 million yuan to 36 million yuan in 2023, a sharp drop of 96.19% to 97.46% year on year
Hot View Biotech (688068.SH) released its 2023 annual performance forecast and is expected to achieve ownership in 2023...
Hot Scene Biology (688068.SH): Currently, there is no brain-computer interface layout
On November 30, Gelonghui (688068.SH) said on an interactive platform that the company, as the first IVD company listed on the Science and Technology Innovation Board, has always used scientific and technological innovation as the company's development concept, strengthened the main in vitro diagnostic business, and expanded new fields and strategic layout based on biotechnology trends. Currently, there is no brain-computer interface.
Hot Scene Biology (688068.SH): Projects related to Alzheimer's disease test reagents are in the R&D and registration stages
On November 30, Gelonghui (688068.SH) said on an interactive platform that projects related to Alzheimer's disease (AD) testing reagents are in the R&D and registration stages. Please continue to pay attention to the company's follow-up announcements for specific progress.
Hot Scene Biology (688068.SH): Currently, collection in Anhui mainly involves HPV, pre-operative eight items, hormones, diabetes, etc., and has little impact on the company
On November 10, Gelonghui (688068.SH) said in an investor survey that the current collection in Anhui mainly involves HPV, pre-operative eight items, hormones, diabetes, etc., and has little impact on the company. It is not ruled out whether the scope will continue to expand in the later stages. The company also continues to pay attention to the latest policies. At the same time, the company has a large variety of innovations, so the impact on revenue will not be significant.
Hot View Biotech (688068.SH) and its subsidiaries obtained 3 domestic Class II medical device registration certificates and 3 overseas qualification certifications in July-October
Hot View Biotech (688068.SH) announced that the company and subsidiaries won the domestic Class II category from July to October 2023...
Hot View Biotech (688068.SH): Net profit for the first three quarters was 54.381 million yuan, a year-on-year decrease of 95.06%
On October 30, Gelonghui (688068.SH) released its report for the first three quarters of 2023. The reporting period achieved operating income of 407 million yuan, a year-on-year decrease of 86.48%; net profit attributable to shareholders of listed companies was 54.381 million yuan, a year-on-year decrease of 95.06%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss of 109.398 million yuan, a year-on-year decrease of 98.99%; basic earnings per share of 0.61 yuan.
Hot Scenery Biology (688068.SH): An innovative small nucleic acid drug for fat loss, sugar reduction, and weight loss, also has a related layout
Glonghui, Oct. 24, 丨 Hot View Biotech (688068.SH) said at an investor relations event that the company's subsidiary, Beijing Yaojing Gene Technology Co., Ltd. is a high-tech biotechnology enterprise focusing on the development and application of innovative drugs in the field of anti-aging. Focusing on metabolic diseases related to aging, it has established multiple core technology platforms such as a new target discovery platform, a high-throughput efficacy evaluation platform, a bioinformation and artificial intelligence development platform, and has laid out a series of innovative nucleic acid drug pipelines. Among them, innovative small nucleic acid drugs for fat loss, sugar reduction, and weight loss also have a relevant layout.
Hot Scenery Biology (688068.SH): It has completed research and development of many respiratory related test reagents, including Mycoplasma pneumoniae, and is in the process of registration
Glonghui, Oct. 24 | Hot Scenery Biotech (688068.SH) said at an investor relations event that the company's C900 and MQ60 single-dose chemiluminescence technology platforms can develop rapid detection reagents for different objects to be tested, and can also guide medical staff. We have completed research and development of many respiratory related test reagents, including Mycoplasma pneumoniae, and are in the process of registering them.
Analysis
Price Target
No Data
